Drugs / BTP-114
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02950064 | Sep 2016 → Apr 2020 | breast neoplasm, ovarian neoplasm, pancreatic neoplasm, prostate neoplasm | Placon Therapeutics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTP-114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02950064 ↗ |
| Modality | Other / unclassified | “a novel platinum product” NCT02950064 ↗ |
| Route | Intravenous | “Intravenous (IV) treatment n 21-day cycles” NCT02950064 ↗ |